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were formed by creatinine clearance measured from 24 h
urine (Table 1). For 13,905 patients who were over 18 years of
age, the number of patients from cut-off values of Scr and
estimated glomerular ﬁltration rate (eGFR) formula at each
CKD stage were compared. The four-variable Modiﬁcation of
Diet in Renal Disease Study equation using Japanese race
factor was applied for eGFR.3
The number of patients per CKD stage, which was
classiﬁed using the newly established Scr cut-off values,
showed very similar results to the number of patients
classiﬁed using eGFR cut-off values (Table 1). In conclusion,
setting the cut-off values would be necessary when applying
Scr to CKD.
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Nephroprevention in acute
phosphate nephropathy
To the Editor: We read the article by Markowitz and
Perazella,1 who masterfully show us the actuality of acute
phosphate nephropathy, this is probably a not uncommon
cause of kidney injury.
Lien2 previously referred to possible strategies to prevent
the side effects of phosphate overload, so we could establish a
preventive strategy:
(1) Avoid use in high-risk patients.1,2 (2) Use the minimal
effective dose,3 the total amount of phosphate excreted in the
urine after the second dose is threefold to fourfold to that
excreted after the ﬁrst dose; this suggests that the second dose
is particularly dangerous,4 so a reduction or replacement with
another agent (magnesium citrate or low-volume polyethy-
lene glycol) would be possible. (3) Increase the interval bet-
ween doses; a 24 h interval reduces the incidence of clinically
relevant hyperphosphatemia, with no loss of efﬁcacy com-
pared with an interval of 9–12 h.3 (4) Avoid dehydration;1,2
clear ﬂuid should be administered; in some centers Gatorade
or E-lyte is recommended (possibly a superior alternative).
Furthermore, monitoring of body weight and urine color is
useful to guide ﬂuid intake. During the procedure an
intravenous line is routinely placed and normal saline could
be given during and after the procedure. (5) Perform serum
biochemistry tests before colonoscopy and measure the renal
function and baseline electrolytes; in high-risk or unstable
patients a control 2 or 3 days after would be necessary. (6)
Finally, consider an alternative bowel-cleansing agent.
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Cognitive-behavioral group
therapy is an effective treatment
for major depression in
hemodialysis (HD) patients
To the Editor: We read with great interest the article by
Duarte et al.1 evaluating a randomized trial on cognitive-
behavioral group therapy (CBT) for major depression in
hemodialysis (HD) patients. In this study group, receiving
CBT had signiﬁcant improvements, compared with the control
group, in the average scores on the Beck Depression Inventory
and Mini-International Psychiatric Interview, and in several
Kidney Disease Quality of Life-Short Form (KDQOL-SF)
dimensions up to 9 months. We would like to raise two issues.
The authors addressed most of the clinical characteristics that
could affect depression in HD patients, with the exception of
one: chronic pain. Chronic pain is a signiﬁcant problem for
B50% of HD patients. The impact of chronic pain on
Table 1 | Number of patients in CKD stage according to the
values of eGFR and Scr cut-off
eGFR (ml/min per 1.73m2) Scr (mg/dl)
CKD stage Cut-off No. (%) Cut-off No. (%)
1 X90 5156 (37.1) p0.7 5767 (41.5)
2 60–89 6990 (50.3) 0.8–1.0 6159 (44.3)
3 30–59 1360 (9.78) 1.1–1.6 1505 (10.8)
4 15–29 172 (1.24) 1.7–2.5 196 (1.41)
5 o15 227 (1.62) 42.5 278 (1.99)
13,905 (100) 13,905 (100)
Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration
rate; Scr, serum creatinine.
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